Structure-based drug design.
There are now many successful examples of the design of new ligands based on knowledge of target protein structures. In most cases those ligands are unsuitable as drugs because of problems of toxicity, stability or bioavailability. The past twelve months have also seen the description of the structures of many proteins which are either known to be targets for existing drugs or have clear potential to be utilized in therapy.